BioCentury | Sep 7, 2018
Clinical News

EyeGate weighing options for EGP-437 after uveitis failure

...strategic options for the product, which is a dexamethasone phosphate ophthalmic solution delivered by the EyeGate...
...was the proportion of patients with an anterior cell count of zero at day 14. EyeGate...
...reduce corneal staining in patients with punctate epitheliopathies due to pathologies such as dry eye. EyeGate...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...Esperion Therapeutics Inc. (NASDAQ:ESPR) Bempedoic acid (ETC-1002) / ezetimibe ASCVD Top-line Ph III data August EyeGate Pharmaceuticals Inc....
BioCentury | Feb 9, 2018
Clinical News

EyeGate's ocular pain and inflammation candidate misses in Phase IIb

...proportion of patients with a pain score of 0 points on day one vs. placebo. EyeGate...
...dexamethasone phosphate ophthalmic solution delivered into ocular tissues by the EyeGate II Drug Delivery System. EyeGate Pharmaceuticals Inc....
...Neurology Molecular target: NA Description: Dexamethasone phosphate ophthalmic solution delivered into ocular tissues by the EyeGate...
BioCentury | Nov 2, 2017
Company News

Management tracks: Melinta, Lundbeck

...Cowen CEO. He succeeds Sung-Wuk Kim, who stepped down but will remain chairman. Ophthalmology company EyeGate Pharmaceuticals Inc....
BioCentury | Apr 28, 2017
Financial News

EyeGate proposes follow-on

...Ophthalmology company EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) proposed to raise up to $11.5 million on April 21 in a...
...million on April 21 in a follow-on underwritten by Wedbush PacGrow. EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG), Waltham, Mass. Alex Himes EyeGate Pharmaceuticals Inc....
BioCentury | Feb 24, 2017
Company News

Eyegate, Valeant deal

...EyeGate granted Valeant exclusive, worldwide rights to manufacture and commercialize EGP-437 in combination with the EyeGate...
...surgery patients. The dexamethasone phosphate ophthalmic solution is in Phase Ib/IIa testing for the indication. EyeGate...
...U.S. Valeant will be responsible for all development and regulatory costs outside of the U.S. EyeGate...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...NDA 1H17 Erytech Pharma S.A. (Euronext:ERYP) Graspa eryaspase Acute lymphoblastic leukemia (ALL) Resubmit MAA Mid-2017 EyeGate Pharmaceuticals Inc....
BioCentury | Aug 15, 2016
Clinical News

EGP-437: Phase Ib/IIa data

...year end, EyeGate plans to start a placebo-controlled trial of EGP-437 in cataract surgery patients. EyeGate Pharmaceuticals Inc....
...Product: EGP-437 Business: Neurology Molecular target: NA Description: Dexamethasone phosphate ophthalmic solution delivered by the EyeGate...
BioCentury | Jul 11, 2016
Financial News

EyeGate completes direct public offering

...Price: $2.25 Shares after offering: 8.8 million Placement agent: H.C. Wainwright Investor: Institutional investor Note: EyeGate...
BioCentury | Mar 28, 2016
Company News

Jade Therapeutics, EyeGate deal

...$300,000 in Jade liabilities and issue 765,728 EyeGate shares valued at $2.9 million based on EyeGate’s...
...is eligible for a $2.2 million milestone payment upon FDA approval of a Jade product. EyeGate...
...to begin a clinical trial in 4Q16. Jade Therapeutics Inc. , Salt Lake City, Utah EyeGate Pharmaceuticals Inc....
Items per page:
1 - 10 of 52
BioCentury | Sep 7, 2018
Clinical News

EyeGate weighing options for EGP-437 after uveitis failure

...strategic options for the product, which is a dexamethasone phosphate ophthalmic solution delivered by the EyeGate...
...was the proportion of patients with an anterior cell count of zero at day 14. EyeGate...
...reduce corneal staining in patients with punctate epitheliopathies due to pathologies such as dry eye. EyeGate...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...Esperion Therapeutics Inc. (NASDAQ:ESPR) Bempedoic acid (ETC-1002) / ezetimibe ASCVD Top-line Ph III data August EyeGate Pharmaceuticals Inc....
BioCentury | Feb 9, 2018
Clinical News

EyeGate's ocular pain and inflammation candidate misses in Phase IIb

...proportion of patients with a pain score of 0 points on day one vs. placebo. EyeGate...
...dexamethasone phosphate ophthalmic solution delivered into ocular tissues by the EyeGate II Drug Delivery System. EyeGate Pharmaceuticals Inc....
...Neurology Molecular target: NA Description: Dexamethasone phosphate ophthalmic solution delivered into ocular tissues by the EyeGate...
BioCentury | Nov 2, 2017
Company News

Management tracks: Melinta, Lundbeck

...Cowen CEO. He succeeds Sung-Wuk Kim, who stepped down but will remain chairman. Ophthalmology company EyeGate Pharmaceuticals Inc....
BioCentury | Apr 28, 2017
Financial News

EyeGate proposes follow-on

...Ophthalmology company EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) proposed to raise up to $11.5 million on April 21 in a...
...million on April 21 in a follow-on underwritten by Wedbush PacGrow. EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG), Waltham, Mass. Alex Himes EyeGate Pharmaceuticals Inc....
BioCentury | Feb 24, 2017
Company News

Eyegate, Valeant deal

...EyeGate granted Valeant exclusive, worldwide rights to manufacture and commercialize EGP-437 in combination with the EyeGate...
...surgery patients. The dexamethasone phosphate ophthalmic solution is in Phase Ib/IIa testing for the indication. EyeGate...
...U.S. Valeant will be responsible for all development and regulatory costs outside of the U.S. EyeGate...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...NDA 1H17 Erytech Pharma S.A. (Euronext:ERYP) Graspa eryaspase Acute lymphoblastic leukemia (ALL) Resubmit MAA Mid-2017 EyeGate Pharmaceuticals Inc....
BioCentury | Aug 15, 2016
Clinical News

EGP-437: Phase Ib/IIa data

...year end, EyeGate plans to start a placebo-controlled trial of EGP-437 in cataract surgery patients. EyeGate Pharmaceuticals Inc....
...Product: EGP-437 Business: Neurology Molecular target: NA Description: Dexamethasone phosphate ophthalmic solution delivered by the EyeGate...
BioCentury | Jul 11, 2016
Financial News

EyeGate completes direct public offering

...Price: $2.25 Shares after offering: 8.8 million Placement agent: H.C. Wainwright Investor: Institutional investor Note: EyeGate...
BioCentury | Mar 28, 2016
Company News

Jade Therapeutics, EyeGate deal

...$300,000 in Jade liabilities and issue 765,728 EyeGate shares valued at $2.9 million based on EyeGate’s...
...is eligible for a $2.2 million milestone payment upon FDA approval of a Jade product. EyeGate...
...to begin a clinical trial in 4Q16. Jade Therapeutics Inc. , Salt Lake City, Utah EyeGate Pharmaceuticals Inc....
Items per page:
1 - 10 of 52